STOCK TITAN

XOMA Corp - XOMA STOCK NEWS

Welcome to our dedicated news page for XOMA (Ticker: XOMA), a resource for investors and traders seeking the latest updates and insights on XOMA.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect XOMA's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of XOMA's position in the market.

Rhea-AI Summary
XOMA (Nasdaq: XOMA) announces cash dividends for its Series A and Series B Cumulative Preferred Stock. Holders of Series A to receive $0.53906 per share, and Series B holders to receive $0.52344 per depositary share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
dividends
-
Rhea-AI Summary
XOMA (Nasdaq: XOMA) announces cash dividends for its Series A and Series B Cumulative Preferred Stock. Holders of Series A to receive $0.53906 per share, and Series B holders to receive $0.52344 per depositary share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.44%
Tags
dividends
-
Rhea-AI Summary
XOMA (Nasdaq: XOMA) announces cash dividends for its Series A and Series B Cumulative Preferred Stock. Holders of Series A to receive $0.53906 per share, and Series B holders to receive $0.52344 per depositary share.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.24%
Tags
dividends
Rhea-AI Summary
XOMA is set to acquire Kinnate Biopharma Inc., adding $9.5 million in cash to its balance sheet and expanding its early-stage programs. The merger agreement includes a cash price per share of $2.5879 for Kinnate stockholders, with the Offer extended until April 2, 2024. The acquisition is subject to certain conditions and is expected to close in April 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.3%
Tags
none
-
Rhea-AI Summary
XOMA is set to acquire Kinnate Biopharma Inc., adding $9.5 million in cash to its balance sheet and expanding its early-stage programs. The merger agreement includes a cash price per share of $2.5879 for Kinnate stockholders, with the Offer extended until April 2, 2024. The acquisition is subject to certain conditions and is expected to close in April 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.16%
Tags
none
-
Rhea-AI Summary
XOMA is set to acquire Kinnate Biopharma Inc., adding $9.5 million in cash to its balance sheet and expanding its early-stage programs. The merger agreement includes a cash price per share of $2.5879 for Kinnate stockholders, with the Offer extended until April 2, 2024. The acquisition is subject to certain conditions and is expected to close in April 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
XOMA Corporation reported strong financial results for Q4 and full year 2023, highlighted by raising $140 million in non-dilutive capital, adding a new commercial asset to their portfolio, and achieving key milestones with partners. The company ended the year with a robust cash position, anticipating significant clinical and regulatory events in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.63%
Tags
earnings
-
Rhea-AI Summary
XOMA Corporation reported strong financial results for Q4 and full year 2023, highlighted by raising $140 million in non-dilutive capital, adding a new commercial asset to their portfolio, and achieving key milestones with partners. The company ended the year with a robust cash position, anticipating significant clinical and regulatory events in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
earnings
-
Rhea-AI Summary
XOMA Corporation reported strong financial results for Q4 and full year 2023, highlighted by raising $140 million in non-dilutive capital, adding a new commercial asset to their portfolio, and achieving key milestones with partners. The company ended the year with a robust cash position, anticipating significant clinical and regulatory events in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.14%
Tags
earnings
Rhea-AI Summary
XOMA Corporation announces participation in upcoming investor conferences in March 2024, with key executives presenting at TD Cowen Health Care Conference and Leerink Partners Global Biopharma Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.42%
Tags
conferences
XOMA Corp

Nasdaq:XOMA

XOMA Rankings

XOMA Stock Data

279.60M
7.95M
0.36%
66.58%
2.36%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Berkeley

About XOMA

xoma has an extensive portfolio of products, programs, and technologies that are the subject of licenses the company has in place with other biotech and pharmaceutical companies. many of these licenses are the result of the company's pioneering efforts in the discovery and development of antibody therapeutics. there are more than 20 such programs that are fully funded by partners and could produce milestone payments and royalty payments in the future. in order to maximize its value in a licensing transaction, xoma continues to invest in x358, an allosteric monoclonal antibody that reduces insulin receptor activity, as the antibody could have a major impact on the treatment of hyperinsulinism. for more information, visit www.xoma.com.